Nan Fung Trinity’s KalVista Pharmaceuticals KALV Stock Holding History

Nan Fung Trinity’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-154,522	Closed	-$3.11M	–	60
2026 Q1	$3.11M	Hold	154,522	–	–	0.34%	53
2025 Q4	$2.5M	Hold	154,522	–	–	0.2%	71
2025 Q3	$1.88M	Hold	154,522	–	–	0.19%	61
2025 Q2	$1.75M	Buy	+154,522	New	+$1.89M	0.21%	56

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nan Fung Trinity's KALV Position: Q2 2026 in Review

Nan Fung Trinity sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 154,522 shares — an estimated $3.11M sold.

Nan Fung Trinity first reported a position in KALV in Q2 2025 and held it in 4 quarters. The position peaked at $3.11M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Nan Fung Trinity reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Nan Fung Trinity sold 154,522 KalVista Pharmaceuticals shares in Q2 2026, an estimated $3.11M.
Nan Fung Trinity first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Nan Fung Trinity's KalVista Pharmaceuticals position peaked at $3.11M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Nan Fung Trinity's 13F filing for Q2 2026, filed 24 Jul 2026.